Leukemia and Myelodysplastic Syndromes Program
Specialized Program of Research Excellence (SPORE) in Leukemia
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-11195589
New lab-to-clinic treatments and tests are being developed for people with leukemias and myelodysplastic syndromes, including immune cell therapies and drugs aimed at specific genetic changes.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11195589 on ClinicalTrials.gov |
What this research studies
This program brings together doctors and scientists at Washington University to turn discoveries about leukemia genes and the immune system into new treatments patients can receive. Work includes clinical trials using CAR‑T cells for T‑cell leukemias, memory-like natural killer (NK) cell therapy for AML that returns after an allogeneic transplant, targeted drugs for myeloid diseases with splicing‑factor mutations, and agents targeting ATR in TP53‑mutated MDS/AML. The team aims to discover biomarkers to guide personalized care and to strengthen clinical and lab infrastructure so lab findings reach patients faster. Many projects combine lab research, analysis of patient samples, and early‑phase clinical trials.
Who could benefit from this research
Good fit: Ideal participants are people with acute leukemias or myelodysplastic syndromes, especially those with relapsed AML after transplant, T‑cell leukemias, or tumors with TP53 or splicing‑factor mutations.
Not a fit: People with non‑blood cancers or stable chronic blood disorders that do not match the specific genetic or relapse criteria are unlikely to benefit from these projects.
Why it matters
Potential benefit: If successful, patients could gain access to new personalized therapies and biomarkers that may reduce relapse and improve survival.
How similar studies have performed: CAR‑T therapy has produced major remissions in B‑cell leukemias, while NK cell therapies and precision drugs for splicing‑factor or TP53‑mutated myeloid diseases are promising but remain early-stage and experimental.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LINK, DANIEL C — WASHINGTON UNIVERSITY
- Study coordinator: LINK, DANIEL C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.